Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว2.1B+ 100.0%
<1.7B <1%
1.7B–1.8B <1%
1.8B–1.9B <1%
$27,755 ปริมาณ
$27,755 ปริมาณ
Apr 17, 2026
<1.7B
No
1.7B–1.8B
No
1.8B–1.9B
No
1.9B–2.0B
No
2.0B–2.1B
No
2.1B+
Yes
No IPO before June 2026
No
2.1B+ 100.0%
<1.7B <1%
1.7B–1.8B <1%
1.8B–1.9B <1%
$27,755 ปริมาณ
$27,755 ปริมาณ
Apr 17, 2026
<1.7B
$1,472 ปริมาณ
No
1.7B–1.8B
$3,525 ปริมาณ
No
1.8B–1.9B
$2,327 ปริมาณ
No
1.9B–2.0B
$2,681 ปริมาณ
No
2.0B–2.1B
$3,265 ปริมาณ
No
2.1B+
$13,975 ปริมาณ
Yes
No IPO before June 2026
$510 ปริมาณ
No
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Apr 14, 2026, 5:05 PM ET
ปริมาณการซื้อขาย
$27,755วันสิ้นสุด
Apr 17, 2026ตลาดเปิดเมื่อ
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$27,755วันสิ้นสุด
Apr 17, 2026ตลาดเปิดเมื่อ
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย